BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keenswijk W, Raes A, Vande Walle J. Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 2018;177:311-8. [PMID: 29288280 DOI: 10.1007/s00431-017-3077-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Keenswijk W, Raes A, De Clerck M, Vande Walle J. Is Plasma Exchange Efficacious in Shiga Toxin‐Associated Hemolytic Uremic Syndrome? A Narrative Review of Current Evidence. Ther Apher Dial 2018;23:118-25. [DOI: 10.1111/1744-9987.12768] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019;7:E15. [PMID: 30634669 DOI: 10.3390/microorganisms7010015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
3 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
4 Harkins VJ, Mcallister DA, Reynolds BC. Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome. Curr Pediatr Rep 2020;8:16-25. [DOI: 10.1007/s40124-020-00208-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Ruggenenti P, Di Marco F, Cortinovis M, Lorini L, Sala S, Novelli L, Raimondi F, Gastoldi S, Galbusera M, Donadelli R, Mele C, Piras R, Noris M, Portalupi V, Cappelletti L, Carrara C, Tomatis F, Bernardi S, Perna A, Peracchi T, Diadei O, Benigni A, Remuzzi G. Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS One 2021;16:e0261113. [PMID: 34928990 DOI: 10.1371/journal.pone.0261113] [Reference Citation Analysis]
6 Balestracci A, Meni Bataglia L, Toledo I, Beaudoin L, Alvarado C. C3 levels and acute outcomes in Shiga toxin-related hemolytic uremic syndrome. Pediatr Nephrol 2020;35:331-9. [PMID: 31475299 DOI: 10.1007/s00467-019-04334-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Štolbová Š, Bezdíčka M, Prohászka Z, Csuka D, Hrachovinová I, Burkert J, Šimánková N, Průhová Š, Zieg J. Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Pediatr 2020;179:1739-50. [PMID: 32424742 DOI: 10.1007/s00431-020-03666-9] [Reference Citation Analysis]
8 Loos S, Oh J, Kemper MJ. Eculizumab in STEC-HUS: need for a proper randomized controlled trial. Pediatr Nephrol 2018;33:1277-81. [PMID: 29774464 DOI: 10.1007/s00467-018-3972-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
9 Lavrek D, Lava SAG, Milani GP, Simonetti GD, Bianchetti MG, Giannini O. Hemolytic-uremic syndrome after Escherichia coli urinary tract infection in humans: systematic review of the literature. J Nephrol 2018;31:919-24. [PMID: 30328581 DOI: 10.1007/s40620-018-0543-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nozaki Y. New Insights Into Novel Therapeutic Targets in ANCA-Associated Vasculitis. Front Immunol 2021;12:631055. [PMID: 33868250 DOI: 10.3389/fimmu.2021.631055] [Reference Citation Analysis]
11 Monet-Didailler C, Chevallier A, Godron-Dubrasquet A, Allard L, Delmas Y, Contin-Bordes C, Brissaud O, Llanas B, Harambat J. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 2020;35:2147-53. [PMID: 31411695 DOI: 10.1093/ndt/gfz158] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]